Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SOX18 | P35713 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589202 | 0.98 | CYP1A2 (0.65) | CYP1A2FFAR1SLC13A5CYP2D6CYP2C19 | |
| SCHEMBL4588706 | 0.86 | CYP1A2 (0.59) | CYP1A2FFAR1SLC13A5PDPK1FFAR4 | |
| SCHEMBL29546077 | 0.85 | CYP1A2 (0.54) | CYP1A2HDAC1HDAC8 | |
| SCHEMBL869422 | 0.85 | CYP1A2 (0.54) | CYP1A2HDAC1HDAC8 | |
| SCHEMBL30403190 | 0.83 | CYP1A2 (0.80) | CYP1A2FFAR1SLC13A5CYP2D6CYP2C19 | |
| SCHEMBL1217683 | 0.83 | CYP1A2 (0.80) | CYP1A2FFAR1SLC13A5CYP2D6CYP2C19 | |
| SCHEMBL632012 | 0.82 | CYP1A2 (0.44) | CYP1A2FFAR1CYP2D6CYP2C19FFAR4 | |
| Hydrochloric Acid SCHEMBL27401796 | 0.82 | CYP1A2 (0.77) | CYP1A2FFAR1SLC13A5CYP2D6CYP2C19 | |
| SCHEMBL3584403 | 0.81 | KEAP1 (0.63) | FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL14814417 | 0.80 | CYP1A2 (0.47) | CYP1A2SLC13A5PDPK1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | CYP1A2 481/4885FFAR1 1540/4885SLC13A5 2786/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | CYP1A2 481/4885FFAR1 1540/4885SLC13A5 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.